Skip to main content

Table 5 Annual rate of severe exacerbations (95% confidence interval), per GOLD stage

From: Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial

Old stage

P-value*

New stage

P-value*

Substage

P-value*

2

0.18 (0.16 - 0.20)

-

A

0.08 (0.05 – 0.12)

-

C1

0.18 (0.12 – 0.25)

-

3

0.39 (0.36 - 0.42)

<0.001

B

0.14 (0.12 – 0.17)

<0.001

C2

0.17 (0.08 – 0.28)

0.71

4

0.54 (0.46 - 0.62)

<0.001

C

0.21 (0.16 – 0.27)

<0.001

C3

0.37 (0.18 – 0.57)

0.001

   

D

0.40 (0.37 – 0.43)

<0.001

D1

0.30 (0.27 – 0.33)

-

      

D2

0.30 (0.26 – 0.36)

0.85

      

D3

0.59 (0.53 – 0.65)

<0.001

AIC

16,019.57

  

15,859.22

  

15,634.93

 
  1. *Wald test of difference with category immediately above. Overall Wald test of equal rates across stages: p < 0.001 for all models. C1/D1: classified in C/D because of lung function impairment; C2/D2: in C/D because of exacerbation history; C3/D3: because of lung function and exacerbation history.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us